GLP-1 Family advanced
GLP-1/Glucagon Dual Agonists
Dual receptor agonists targeting both GLP-1 and glucagon receptors for enhanced metabolic effects including weight loss and hepatoprotection.
By Encyclopeptide Editorial | 1 min read
GLP-1 glucagon dual-agonist obesity NASH
Overview
GLP-1/glucagon dual agonists are next-generation incretin-based therapies targeting both GLP-1 and glucagon receptors for synergistic metabolic effects.
Rationale
- GLP-1 receptor: Enhances insulin secretion, promotes satiety
- Glucagon receptor: Increases energy expenditure, promotes hepatic fat oxidation
- Combined effects: Synergistic weight loss, improved hepatic steatosis
Clinical Candidates
| Candidate | Developer | Phase |
|---|---|---|
| MEDI0382 | AstraZeneca | Phase 2 |
| SAR425899 | Sanofi | Phase 2 |
| VB4665 | Zealand/Viking | Phase 1 |
Chemical Identity
| Property | Value |
|---|---|
| Name | GLP-1/Glucagon Dual Agonists |
| Category | GLP-1 Family |
References
- Encyclopeptide Database. “GLP-1/Glucagon Dual Agonists” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about GLP-1/Glucagon Dual Agonists with interactive quizzes on Wikipept.
Take a Quiz on Wikipept